The Itch Factor: Why Relief Can’t Wait in Atopic Dermatitis

In this episode of Topical Conversations, Matthew Zirwas, MD, and Raj Chovatiya, MD, discuss one of the most important, and sometimes underappreciated, aspects of atopic dermatitis (AD) management: rapid itch relief. Despite the progress made with targeted therapies, many dermatologists may still overlook how profoundly itch drives disease burden, adherence, and patient trust. Drs Zirwas and Chovatiya share practical approaches for evaluating itch severity, setting realistic expectations, and understanding how new-generation therapies are impacting the conversation around early symptom improvement.

Why itch still warrants more attention in AD

Despite the numerous treatment options for AD, Drs Zirwas and Chovatiya agree that itch remains an under-discussed symptom during dermatology visits. Dr Chovatiya points out that while dermatologists often assume they’re addressing itch adequately, in practice, they may not be asking the right questions about itch severity or fully exploring its impact on quality of life.

Dr Zirwas adds that while the Numeric Rating Scale (NRS) for itch is useful in research, it’s less practical in routine clinical settings where patients are seen only every few months. Instead, he recommends a more straightforward, contextual approach: asking patients whether their itch is none, mild, moderate, or severe. He likens mild itch to a single mosquito bite, moderate to 20 mosquito bites or some poison ivy, and severe to widespread poison ivy or hundreds of bites. Framing the question this way, he explains, helps patients describe their experience more accurately and meaningfully.

The broader impact: itch as a holistic problem

Dr Chovatiya emphasizes that itch is not a surface-level symptom, but rather drives a cascade of issues including sleep disturbance, fatigue, mood changes, anxiety, and depression. Persistent itch can also erode trust between patients and providers when relief isn’t achieved quickly enough, leading to frustration with otherwise effective treatment plans.

Both dermatologists stress that understanding itch’s impact on quality of life is essential not only for patient empathy but also for maintaining long-term treatment adherence.

A new era of therapies and a shift in expectations

The landscape of AD therapy has evolved dramatically, introducing multiple biologic and small-molecule options that challenge old assumptions about speed and safety. Dr Chovatiya notes that dermatologists historically viewed biologics as “safe but slow,” but that perception no longer holds true. Today’s therapeutic arsenal includes IL-4/IL-13 inhibitors, IL-13 inhibitors, IL-31 inhibitors, and potentially soon, OX40 inhibitors, which are all capable of rapid and meaningful itch improvement.

When discussing the pace of itch relief, both agree that while oral JAK inhibitors may deliver the fastest onset, biologics now demonstrate impressive early itch improvement as well. Dr Chovatiya points to real-world data showing that many patients experience noticeable relief early in their biologic therapy, not just lesion improvement.

Tralokinumab and rapid itch relief

Dr Zirwas highlights that among available biologics, tralokinumab provides balanced performance across efficacy, safety, and speed. He notes that data from the ECZTRA trials demonstrated separation from placebo within the first few doses, confirming that tralokinumab delivers meaningful early itch relief while maintaining long-term control and a favorable safety profile.

While tralokinumab has sometimes been perceived as slow-acting, both dermatologists emphasize that this perception is not supported by clinical or real-world evidence. In practice, all approved biologics, including tralokinumab, can provide rapid and sustained itch improvement.

Early itch relief is foundational to effective care

Drs Zirwas and Chovatiya conclude that early itch relief is not just about comfort; it’s a cornerstone of patient satisfaction, adherence, and confidence in treatment. For patients with moderate to severe AD, agents like tralokinumab demonstrate that it’s possible to achieve rapid itch relief, visible skin improvement, and long-term disease control, all while maintaining a strong safety profile.

Key takeaways

• Itch assessment deserves more attention: Despite being the hallmark symptom of AD, many dermatologists don’t ask enough about itch severity or its daily impact on quality of life
• Qualitative scales may be more practical than numeric ones: Replacing the Numeric Rating Scale with simple categories paired with real-life comparisons helps patients describe their itch more accurately
• Itch affects more than the skin: Persistent itch contributes to sleep loss, mood changes, and diminished confidence in treatment, highlighting the need for early and meaningful relief
• Modern therapies deliver faster relief than once believed: Biologics such as tralokinumab have shown clinically relevant itch improvement within the first few doses
• Balance matters: Choosing treatments that address itch, skin clearance, safety, and adherence supports both short-term comfort and long-term control in patients with moderate-to-severe AD